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AbsTrACT
background Drug- resistant tuberculosis burdens fragile 
health systems in sub- Saharan Africa (SSA), complicated by 
high prevalence of HIV. Several African countries reported 
large gaps between estimated incidence and diagnosed 
or treated cases. Our review aimed to identify barriers and 
facilitators influencing diagnosis and treatment for drug- 
resistant tuberculosis (DR- TB) in SSA, which is necessary to 
develop effective strategies to find the missing incident cases 
and improve quality of care.
Methods Using an integrative design, we reviewed 
and narratively synthesised qualitative, quantitative and 
mixed- methods studies from nine electronic databases: 
Medline, Global Health, CINAHL, EMBASE, Scopus, Web 
of Science, International Journal of Tuberculosis and 
Lung Disease, PubMed and Google Scholar (January 
2006 to June 2019).
results Of 3181 original studies identified, 55 full texts were 
screened, and 29 retained. The studies included were from 
6 countries, mostly South Africa. Barriers and facilitators to 
DR- TB care were identified at the health system and patient 
levels. Predominant health system barriers were laboratory 
operational issues, provider knowledge and attitudes and 
information management. Facilitators included GeneXpert 
MTB/RIF (Xpert) diagnosis and decentralisation of services. 
At the patient level, predominant barriers were patients 
being lost to follow- up or dying due to lengthy diagnostic and 
treatment delays, negative public sector care perceptions, 
family, work or school commitments and using private sector 
care. Some patient- level facilitators were HIV positivity and 
having more symptoms.
Conclusion Case detection and treatment for DR -TB 
in SSA currently relies on individual patients presenting 
voluntarily to the hospital for care. Specific interventions 
targeting identified barriers may improve rates and 
timeliness of detection and treatment.
InTroduCTIon
Drug- resistant tuberculosis (DR- TB) is a major 
threat to global health as it undermines gains 
in TB control, and is especially burdensome 
to health systems in resource- limited settings.1 
Defined as TB resistant to both isoniazid and 
rifampicin, it is the leading cause of deaths 
summary box
What is already known?
 ► Globally, only 39% and 32% of the estimated 
drug- resistant tuberculosis (DR- TB) patients are 
diagnosed and started on appropriate treatment, 
respectively.
 ► Ten high burden countries in Africa contributed 12% 
of the estimated global incident cases in 2018, with 
54% of these in only Nigeria and South Africa.
 ► For patients who are diagnosed and placed on treat-
ment, delays in access to diagnosis and treatment 
were up to several months in some sub- Saharan 
African countries.
What are the new findings?
 ► Laboratory operational challenges as well as inad-
equate healthcare worker knowledge, attitude and 
skills were the predominant barriers noted at the 
health system level.
 ► Predominant patient- level barriers included loss to 
follow- up and death, as well as inability to pay care- 
related costs.
 ► Availability of newer diagnostic tools was the pre-
dominant health- level facilitator of quicker diagnosis 
and treatment; however, this did not always trans-
late to significantly higher rates of diagnosis and 
treatment.
What do the new findings imply?
 ► Implementers and policymakers need to better un-
derstand and address various issues that impact 
DR- TB care at different levels, in order to maximise 
the impact of new care innovations.
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Figure 1 Study selection. SSA, sub- Saharan Africa; TB, tuberculosis.
due to antimicrobial resistance and took an estimated 
214 000 lives in 2018.2 The 2018 United Nations High- 
Level resolution to ‘end TB including DR- TB’ by acceler-
ating access to affordable prevention and care, is in line 
with earlier goals including the Sustainable Development 
Goals (SDGs) and The End TB Strategy.3–5 To meet these 
goals, it is essential to synthesise the growing evidence on 
barriers and facilitators to DR- TB care.
DR- TB is more difficult to diagnose and treat than 
drug- susceptible TB and is often associated with up 
to 5.5 times higher treatment costs, longer treatment 
courses and lower treatment success rates.1 2 6 Glob-
ally, only 39% and 32% of the estimated patients diag-
nosed with DR- TB are started on appropriate treatment, 
respectively.2 Ten high burden countries (HBCs) in sub- 
Saharan Africa (SSA) contributed 12% of the 484 000 
estimated incident cases in 2018, mostly in Nigeria and 
South Africa. Nigeria and Mozambique were among 
10 countries contributing 75% of the global treatment 
enrolment gap.2
Gaps in TB care were notedly higher in Africa, where 
the HIV- associated TB incidence is highest, as HIV 
further complicates TB care. Of 14 countries classi-
fied by WHO as HBCs for TB, DR- TB and HIV, 8 are in 
Africa.2
For patients with DR- TB who are diagnosed and 
treated, several studies have reported delays in access 
running into several months in several SSA countries.7–10 
These delays, occurring at patient and health system 
(provider) levels, contribute to increased morbidity, 
infection transmission, loss to follow- up and poorer treat-
ment outcomes.11 12 This review examines any synthe-
sised qualitative and quantitative literature, with a view to 
inform policy and practice in SSA.
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Our review question was ‘What are the patient or 
provider factors associated with delays in tuberculosis 
diagnosis and treatment in sub- Saharan Africa?’.
MeTHods
We used a mixed- methods systematic review with an 
integrative approach13 to analyse data from qualitative, 
quantitative and mixed- methods literature and assessed 
quality using the COnsolidated criteria for REporting Qual-
itative research for qualitative studies (COREQ), Strength-
ening the Reporting of Observational Studies in Epidemiology 
-Combined tool (STROBE) and Mixed Methods Appraisal 
Tool (MMAT) tools, respectively.14–16
We registered the systematic review protocol in the 
PROSPERO database (https://www. crd. york. ac. uk/ 
PROSPERO/ display_ record. php? RecordID= 106875).
search strategy
Using a combination of key terms, we searched nine 
electronic databases: CINAHL, Medline, Embase, Global 
Health, Scopus, Web of Science, International Journal 
of Tuberculosis and Lung Disease, PubMed and Google 
Scholar between January 2006 and June 2017, updating 
the search in June 2019. The year 2006 was used as this 
was the date of the first WHO publication guiding the 
programmatic management of DR- TB.
The Population, Intervention, Comparator and 
Outcomes (PICO) framework17 and key search terms 
used are summarised in online supplementary annex 
1. The initial search terms were piloted and refined in 
CINAHL, and replicated in other databases, using appro-
priate strategies specific to each. The public health 
librarian at the University of Montreal School of Public 
Health validated this process.
study selection and inclusion criteria
We selected studies (figure 1) based on our inclusion 
criteria and PICO framework (online supplementary 
annex 1). Search results were downloaded into EndNote 
X7.7 and deduplicated. Titles and abstracts were 
screened, and full texts reviewed to determine studies for 
inclusion, and reasons for exclusion. All discrepancies or 
uncertainties were discussed and resolved by consensus 
during the final review.
data extraction
Descriptive and analytical data were extracted (table 1). 
Study findings and outcomes were grouped quantita-
tively and qualitatively (table 2). Paired access dimen-
sions and recommendations for some identified barriers, 
drawn from the studies themselves, were presented in the 
context of the healthcare access model by Levesque et al 
(table 3).18 Finally, a summary of access factors based on 
perceived importance and frequency of appearance19 are 
presented in figure 2, online supplementary annex 3.
Quality assessment
We assessed the quality of studies through different 
critical quality appraisal tools based on study designs. 
Consensus was reached by discussion. For quantitative 
studies, we used the STROBE combined tool.14 The 
COREQ15 and the MMAT was used to appraise mixed- 
methods studies.16 The quality assessment are provided 
in online supplementary annex 2.
The overall quality assessments of ‘A’ for high (>70%), 
‘B’ (50%–69%) for medium or ‘C’ (<50%) for low were 
assigned based on independent evaluation by at least 
two reviewers for each study. The STROBE, COREQ and 
MMAT tools have been used in several systematic reviews 
as a basis for excluding low quality studies.20–22
Conceptual framework
We adapted a conceptual framework, mapping the TB 
care continuum from symptom onset to treatment initi-
ation23 to four corresponding dimensions of access at 
the provider and patient levels,18 24 and aligned these 
to identified barriers and facilitators from our review 
(figure 3). We explained provider factors using the six 
health systems building blocks described by WHO.25 
Patient- level barriers and facilitators were described using 
the Andersen and Newman individual determinants of 
healthcare utilisation.26
data analysis
We used an integrative approach13 to develop a narrative 
analysis of key findings from qualitative, quantitative and 
mixed- methods studies, due to the high heterogeneity of 
selected studies. We repeatedly screened, coded and cate-
gorised data from each study in four ways: table 1 gives the 
selected study overview—first author (year) and country, 
research design, population, intervention (when appli-
cable), summary of barriers and facilitators, the level of 
care (diagnosis or treatment) in which they occurred and 
the dimensions of care (provider or patient), the main 
findings and the quality assessment score.
In table 2, we separated quantitative and qualitative 
findings for each identified factor. We reported associ-
ations that were statistically significant or relevant to 
our analysis and included representative quotes where 
available.
In table 3, we used the healthcare access model by 
Levesque et al18 24 to categorise data into four provider 
and patient paired dimensions: approachability/ability 
to perceive; acceptability/ability to seek; availability/
ability to reach; affordability/ability to pay and finally 
appropriateness/ability to engage. The paired dimen-
sion of approachability and ability to perceive relates 
mostly to knowledge of providers and patients about 
services. Acceptability and the corresponding ability to 
seek focuses on cultural and social aspects that influence 
people’s decisions to use health service and the personal 
autonomy and agency to make these decisions. Avail-
ability and the ability to reach refers to the physical exis-
tence of health systems and health workers, as well as the 
physical mobility and work flexibility of patients to reach 
available health resources. The dimensions of afford-
ability and the corresponding ability to pay reflects the 
copyright.
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financial implications of health services and the capacity 
on the side of patients to bear these costs.18
To synthesise the factors identified across the variety of 
studies, we ranked each barrier and facilitator based on its 
importance within each study and the number of studies 
where it appeared (figure 2, online supplementary annex 
3). A factor is assigned the maximum score of 3 if it affects 
>50% of participants or has an OR of <0.65 or >1.5 for 
quantitative studies; and deemed as being of high impor-
tance or repeatedly mentioned across participant types. 
Factors are assigned a 2 if they affect 25%–50% of partici-
pants, or OR 0.65–0.8 or 1.25–1.5 for quantitative studies; 
or were deemed of moderate importance or by default 
when mentioned but not rated in qualitative studies. 
Factors were assigned 1 if affecting few participants and a 
zero if not mentioned. These scores were added for each 
study where the factor appeared. A similar method for 
synthesising mixed- methods reviews has been previously 
described.19
Patient and public involvement
Patients or members of the public were not involved in 
this research.
resulTs
After an initial search yield of 3181 unique studies, 55 full 
texts met screening criteria, and a final selection of 30 
articles were retained (figure 1).
study characteristics
The majority of the included studies were conducted in 
South Africa (n=20), with Zimbabwe (n=3), Tanzania 
(n=3), Nigeria (n=2), Kenya (n=1) and Gabon (n=1) 
making up the rest. These six countries represent 49.5% 
of the 77 000 estimated DR- TB incident cases in Africa 
in 2018.2 There were 3 qualitative, 22 quantitative and 5 
mixed- methods studies. Among the quantitative studies, 
there were 13 retrospective, 3 prospective and 1 mixed 
cohort studies, and 5 cross- sectional surveys. All of the 
three qualitative studies employed in- depth interviews, 
with one study including focus group discussions. Five 
studies examined access factors related to DR- TB treat-
ment only, 9 on DR- TB diagnosis only and 16 focused on 
both diagnosis and treatment. Factors impacting access 
were identified at provider (n=30) and patient (n=24) 
levels. Sixteen studies explored the influence of diag-
nostic tools on laboratory turnaround time and on treat-
ment initiation. Table 1 summarises the study character-
istics for this review.
Quality appraisal
The results of our quality assessment are shown in online 
supplementary annex 2. Out of a total of 22 quantitative 
studies, 20 were classified as A, with 2 scoring B based on 
the STROBE criteria.14 The two qualitative studies scored 
A and B using the COREQ tool,15 with one study, graded 
a C, excluded. Using the MMAT tool,16 four studies were 
graded A and one as B in mixed methodology.
Provider factors affecting dr-Tb diagnosis and treatment
In all 29 retained studies, the most dominant factors 
affecting DR- TB care were provider- related (table 2, 
figure 3). Our study highlighted a wide range of specific 
problems reflecting nearly all aspects of service delivery 
and health workforce with a few issues related to leader-
ship and governance, and management of health prod-
ucts and information.
Service delivery was, by far, the most predomi-
nant provider- related barrier. Laboratory10 27–32 and 
clinic10 28 31 33 34 operational challenges, as well as centrali-
sation of services7 28 30 32 35–39 and poor linkage between the 
public and private sector,29 32 hampered care. Inadequate 
provider knowledge, skill and adherence to national 
guidelines were also recurring themes.10 27–30 32 34 40–44 
These are discussed in more detail in the context of the 
paired dimensions of access.
Patient-level factors influencing dr-Tb diagnosis and 
treatment
Most patient- level barriers were related to predis-
posing characteristics including knowledge and percep-
tions,29 39 40 45 HIV status,7 38 43 44 presenting symptoms,44 46 
gender44 46 and age27 43 44 46; and enabling characteristics 
including geographic location,10 27 28 30 43 47–49 life commit-
ments29 32 40 and the ability to pay for transportation or 
services.29 32 39 40 A few need and health- seeking character-
istics were also identified relating to treatment refusal,36 
and choosing private sector care.10 32
Paired access dimensions
We have summarised access factors and recommenda-
tions from the reviewed studies into four paired dimen-
sions (table 3).18
Approachability/ability to perceive
We found that provider and patient knowledge about 
DR- TB services18 were hindered by inadequate leader-
ship and governance, provider training, service delivery, 
patients’ predisposing and need characteristics.18 25 26 
At the systems level, inadequate patient tracking, refer-
rals and follow- up, poor provider knowledge about 
the service requirements and inadequate guideline 
availability and non- adherence were identified chal-
lenges.10 28 31 32 34 35 40–43 46 50 Patients’ ability to perceive 
the right services were hampered by health illiteracy, 
poor perceptions of services, distrust and unmet expec-
tations.31 39 40
At the health systems level, the consequences of poor 
leadership and governance were reflected in patient 
non- referral, misdiagnosis and treatment with ineffec-
tive regimens.32 42 Guidelines awareness, availability and 
expansion to include low- risk groups were shown to 
improve access.32 42 47 51
Provider knowledge, skills and attitude were repeatedly 
shown to influence access and was a predominant theme 
(figure 3). Delayed or inadequate training, inexperi-
ence and poor supervision of health workers influenced 
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Figure 2 Summary of barriers and facilitators influencing drug- resistant tuberculosis (DR- TB) diagnosis and treatment in sub- 
Saharan Africa (SSA), ranked both on frequency of appearance and perceived importance.
HCW, healthcare worker; KSA, knowledge, skills and attitude. *Inconclusive results; see table 2.
product availability, diagnosis and treatment.10 28 29 32 40 41 
Poor adherence to DR- TB testing algorithm, treatment 
guidelines or referral procedures hampered diagnosis 
and treatment,27 30 32 34 42–44 with patients often left undi-
agnosed, untreated, treated with ineffective drugs or only 
after serious complications.32 42
At the patient level, poor perception of the public 
sector (overburdened, long waiting times, negative staff 
attitudes, poor confidentiality, lack of privacy, risk of 
infection) were some reasons why patients were avoiding 
the public sector hospitals where DR- TB services could 
be accessed.29 39 40 45
Wrong disease attribution, symptom minimisation, non- 
disclosure, treatment refusal and choosing traditional 
care were also noted as delaying care- seeking.10 32 36 45
Patients seeking care first in the private sector (private 
hospitals, pharmacies, patent medicine vendors, tradi-
tional healers), where the index of suspicion was lower, 
instead of public sector, where services were available, 
had lower odds of getting tested.44
Acceptability/ability to seek
Our review found that although provider attitudes and 
practice were implicated, patients’ predisposing charac-
teristics were predominant in influencing their decisions 
to use health services.18 25 26 Acceptability challenges were 
related to poor healthcare worker norms and attitude 
including confidentiality concerns, stigma and how the 
care patients received were influenced by their symp-
toms7 43 44 46 or sociodemographic characteristics.40 45 
Patient’s ability to seek were influenced by their sociode-
mographic characteristics, personal, cultural and social 
values, disclosure, work and family commitments, use 
of private sector alternatives and fear of poor infection 
control.27 29–33 36 39 40 44 50 51
At the provider level, stigma and discrimination 
towards providers from other hospital workers, and from 
provider to patients compromised access to and quality 
of care.10 32 45
At the patient level, living with HIV had conflicting 
results. Some studies found no association between HIV 
status and having a DST done, nor with time to treat-
ment.48 52 However, two studies found patients with HIV 
having overall higher odds of receiving a TB diagnosis.38 44 
However, HIV- positive patients had longer times to treat-
ment or were less likely to initiate treatment,7 43 except in 
one study where treatment initiation rates were higher 
than in HIV- negative patients.50 In qualitative studies, 
the fear of an HIV diagnosis delayed health- seeking, and 
some patients with HIV were seen to have an increased 
awareness of TB risk.32
Patients presenting with more than any two of TB symp-
toms (cough, fever, weight loss, night sweats), retreatment 
cases and undernourished children were more likely to 
be screened for TB on hospital presentation for other 
reasons than those presenting with fewer symptoms, 
new cases and well- nourished children, respectively.44 46 
Smear- positive cases and more symptomatic patients were 
more likely to have a DST done.27 47 Half of the time, 
previous TB led to faster symptom recognition and care- 
seeking.32 In one study, being pregnant made accessing 
DR- TB care more difficult as providers refused to initiate 
any DR- TB- related care.32
Patient agency and persistence in demanding DR- TB 
testing where none was offered was noted as a facilitator 
to DR- TB healthcare, and this was linked to HIV positivity 
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Figure 3 An adapted conceptual framework of identified barriers and facilitators to to DR- TB care.
or prior knowledge of the disease, either through an 
earlier TB infection or knowing another patient with 
DR- TB.32
Results linking access to patient gender and age were 
largely inconclusive. In several studies, neither patient 
gender nor age were found to be associated with diag-
nosis timeliness or rates,27 30 52 nor with treatment 
initiation rates or timeliness.36 39 43 48 There were some 
indications that females44 46 or children whose mothers 
are the primary TB source,40 or younger age27 43 44 46 were 
less like to be diagnosed or treated (table 2). One study33 
found children to be more likely to initiate treatment 
than adults.
One study noted other contextual patient factors that 
were seen to influence DR- TB care. In South Africa, 
ethnicity and cigarette smoking—with children failing 
to attend clinic appointments more frequently from 
coloured ethnicity and homes with cigarette smokers. 
No particular reason was given for these differences, 
however, it was acknowledged that these were markers 
for other socioeconomic and cultural factors needing 
further research.40
Availability/ability to reach
These were mostly related to service delivery, access to 
health products and patient tracking on the provider 
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side and geographic access and life commitments on the 
patient side.18 25 26 Specific health system barriers were 
related to coverage, bed spaces and centralisation of 
services; inadequate availability and coverage of health 
products—equipment and technology, advanced diag-
nostics and medications; shortages of health personnel; 
clinic and laboratory errors.7 10 27 28 30–35 37–40 45 47 49 51–53 
Patients were prevented from reaching health services 
when they lived in inaccessible locations or faraway 
distances, lack of social support and difficulty in trans-
portation, poor sputum specimen, out- migration or 
death.27 32 33 36 37 40 42 45 49–51
Laboratory operational challenges were the most reoc-
curring barriers to care (figure 3). Specimen contami-
nation, loss of viability, difficulty in packaging, batching, 
transportation and delivery of samples10 27 28 delayed diag-
nosis. Not requesting tests, incomplete records, delayed 
results were other barriers preventing patients form 
accessing care.10 28–32 Staff shortages, especially laboratory 
staff, contributed to diagnostic delays and patient waiting 
times.10 28 45 There were significant geographical varia-
tions, mostly in laboratory operations, which impacted 
referral, diagnosis and treatment rates.10 27 28 30 33 43 47–49 
National programme support to health centres and using 
expedited mail service for sample transportation were 
helpful in reducing laboratory delays.28
Poor data management affected patient linkage to care 
and reporting. Errors including missing patient records 
in diagnosis or treatment registers, irretrievable request 
forms, incomplete data entry led to misplaced results, 
untraceable patients and poor linkage to care.10 28 31 33 34
Inadequate coverage and maintenance of diagnostic 
equipment, as well as power outages hampered diag-
nostic capacity10 28 44 45 and staff motivation.45 Where 
available, using the Xpert notification system improved 
team communication and facilitated diagnosis.31
Centralisation (in few specialised health centres) of 
GeneXpert MTB/RIF (Xpert) or other pretreatment 
requirements like X- rays, and a lack of integration, 
increased diagnosis time28 39 and resulted in negative 
patient experiences.45 Service decentralisation (wide-
spread availability of services, and at the different health-
care levels) was, consequently shown to be a major 
facilitator of access (figure 3), reducing time to diagnosis 
and treatment and increasing diagnosis rates.7 30 32 35–38 
However, patients initiating care at higher facilities had 
lower odds of getting tested or initiating treatment.36 44 50 
Treatment initiation rate was highest among patients diag-
nosed directly through TB hospitals.43 In one setting, 
timeliness of treatment was higher among patients initi-
ated as inpatients compared with outpatients.33
The public sector had longer waiting times pushing 
patients to access care in the private sector, with poor 
linkages between the two.29 32 Failure or delay in tracking 
patients, and unavailability of results at appointments 
prevented access.10 32
Access to newer diagnostics was the principal facili-
tator of access identified (figure 3). There was an overall 
consensus that the use of older diagnostic tests (eg, X- rays, 
drug susceptibility testing (DST) or line probe assay 
(LPA)), when compared with Xpert, was associated with 
longer times to diagnosis and treatment.7 28 37–39 41 43 51–53 
With the exception of one study,35 Xpert implementa-
tion did not result in corresponding increases in diag-
nosis and treatment rates.7 37 43 54 Also, the average time 
to DR- TB care remained significantly higher than the 
national targets in most settings.33 39 41 43 52 53
At the patient level, several studies noted high rates of 
patients being lost to follow- up or dying before treatment 
due to non- referrals, data errors, prolonged pretreat-
ment processes and delayed care- seeking.31 42 50
Geographical location of patients was also identified as 
an access barrier. Patients in an urban/formal settlement 
accessed care more compared with those in rural, informal 
settlements or prison. Other variations were likely linked 
to the healthcare location, as noted above.32 33 50 53 Signifi-
cant variations in accessing diagnosis and treatment were 
due to geographical locations of the patients, with urban 
residence or proximity to care facility increasing likeli-
hood of testing and treatment, as well as reducing time to 
results and treatment.10 27 28 30 43 47–49
Family, work or school commitments were seen to 
prevent or interrupt the care process, while the presence 
of family support enabled care- seeking.29 32 40
Affordability/ability to pay
The financial implications of services were mostly related 
to the enabling characteristics of patients to pay for care 
including transportation costs.18 25 26 In our review, we 
found difficulties in paying for transport to health facil-
ities, and high opportunity costs borne by patients.32 40
Ease of access and cost of health services were some 
reasons for choice of facility. A lack of money for trans-
port, travel time and numerous bus transfers influ-
enced whether they returned to the facility after initial 
visit.29 39 40 Seeking care in the private sector was noted 
as contributing to the high costs of care for patients, 
as some go the public sector, where care was perceived 
as poor, only when they could no longer afford private 
care.32 In another study where high costs of care was 
noted, majority of the patients sought care in the private 
sector.29
Discussion
Our review synthesises the diverse knowledge base about 
obstacles to DR- TB care in SSA to create a consolidated 
understanding to inform practice. It highlighted several 
health system and patient barriers.
Our key findings include the role of rapid diagnostics 
and laboratory operational issues play in facilitating or 
impeding access. Rapid diagnostic tools, particularly 
Xpert, play a central role in accessing DR- TB diagnosis 
and treatment, and their absence would constitute a 
significant barrier to receiving care.28 38 39 The introduc-
tion of these tools has led to a significant reduction in 
times to care for DR- TB.7 38 39 43 51–53 However, although 
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times were shortened, patients still experienced unneces-
sary delays in accessing care. The gains of rapid diagnostic 
technology have, so far, not translated into a commensu-
rate increase in rates of detection and treatment.7 37 39 43 
These were likely due to the range of laboratory oper-
ational errors identified,10 27–32 and which need to be 
targeted to improve case finding and treatment rates.
Our review data reveal several missed opportunities 
for screening and treatment initiation.7 32 34 46 These 
contribute to the global ‘missing cases’, perpetuate trans-
mission and highlight critical gaps in the care cascade. For 
example, the inadequate linkage between the private and 
the public sector occur before access to testing and are 
beyond the scope of rapid diagnostics. They contribute 
to the persistence of low diagnostic and treatment rates 
despite Xpert implementation.
Results for age and sex were found to be divergent, 
as many studies found both factors not significant in 
impacting care. In the studies where age was significant, 
younger age was mostly a barrier,27 43 44 46 except in one 
study33 where the programme prioritised children and 
other high- risk groups for Xpert diagnosis and inpatient 
care. Where most studies found sex not associated with 
DR- TB care, some found being female or a child or a 
female patient with DR- TB to be a barrier to care.27 40 44 46 
One study found females more likely to have earlier diag-
nosis, likely due to care- seeking behaviours.52
Several contextual factors like language, religion and 
culture were not identified by the studies included in 
this review. Geographic locations of the health centres 
and of the patients themselves were identified as influ-
encing access to care, and this has been reported by 
other authors.55 56 Ethnicity and lifestyle were identified 
in one study to influence access, likely due to socioeco-
nomic and cultural implications.40 The lack of qualitative 
data on the influence of sex and age on access makes it 
difficult to draw conclusions about whether the effects 
seen were due to contextual factors.
To improve patient- level barriers calls for a close 
examination of social determinants like poverty 
and geographic access as an addition to biomedical 
approaches, as recommended by the Commission 
on Social Determinants of Health (CSDH).57–59 The 
burdens of infectious diseases like TB are disproportion-
ately borne by patients with certain sociodemographic 
characteristics. For example, rural patients bear higher 
treatment costs and report more difficulty with trans-
port to health centres for treatment.60 61 Demographic 
characteristics such as gender, poverty or ethnicity often 
interact in complex ways, further increasing vulnera-
bility and disadvantage.62 63 Inadequate knowledge of 
DR- TB disease and health services was also identified as 
a major cause of poor health- seeking behaviour among 
patients. Raising public awareness of symptoms and 
available resources may contribute to reducing these 
delays.
The biomedical approach, which focuses more on 
the use of technology to manage diseases needs to be 
combined with efforts to tackle root causes and social 
determinants of DR- TB disease.60 64
Our findings indicate that, in order to overcome 
prevailing barriers to care, innovative diagnostic tools 
and treatment require functional, efficient and accessible 
health systems to reach and track patients who are, them-
selves, informed and motivated. The high susceptibility 
of individuals getting harmed from DR- TB, due to the 
complex interaction between risk factors and available 
resources, is manifested in their inability to manage risks 
or recover from the disease effectively.63 This is corrobo-
rated by many of the reviewed studies in which diagnosed 
patients died before they could be initiated on life- saving 
treatment.31 36 42 50 This highlights the fact that DR- TB 
continues to be characterised by avoidable morbidity 
and deaths, especially in SSA, and must be treated with 
urgency. The raison d’être of rapid diagnostic methods is to 
improve these outcomes by facilitating quicker diagnosis 
and treatment. Xpert implementation did not translate 
to universal increases in diagnosis and treatment rates, 
presenting a significant setback and missed opportunity 
in the control of DR- TB.
Gaps in the capacity of the health system to deliver care 
need to be closed. This would require significant invest-
ments at lower levels of care towards more decentralised 
and ambulatory models of care. In order to fund these 
efforts, SSA governments need to prioritise and increase 
health investments and mobilise resources to fund TB 
control.
strengths and limitations
The strengths of this review include the adaptation of our 
conceptual framework to align factors influencing DR- TB 
care with other well- known frameworks in the field of 
healthcare access and systems strengthening,18 25 26 using 
a mixed- methods approach.
This review has a few limitations. First, due to the hetero-
geneity of study methods and outcome variables, neither 
summary measures (eg, effect size) nor pooled analysis 
for specific interventions were determined, as the studies 
were not sufficiently comparable to each other. Another 
limitation is related to the location of the studies. Our 
search showed a dominance of studies from South Africa, 
with only two from Nigeria, and none from Angola, DR 
Congo, Ethiopia, Kenya, Mozambique, the other TB/
DR- TB/HIV HBCs in the region. This may have affected 
the generalisability of our findings within the region, 
as there are likely other barriers in the different other 
settings that were not identified. However, the relatively 
higher HIV burden in South Africa, and the country’s 
quick adoption of newer diagnostics and medications 
could serve as an example for these other countries as 
they scale- up services for DR- TB.
ConClusIons
The implications of these findings are sobering; they 
suggest that despite significant progress in cutting down 
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time to diagnosis and treatment by using rapid diagnos-
tics, this is not enough, in itself, to remove all delays to 
diagnosis, as other barriers persist in the health system.
WHO recognises that DR- TB is a social justice problem 
and as a threat to global health security, requiring 
universal access to the tools and services needed for 
rapid diagnosis, treatment and care.65 Diagnosis and 
treatment for DR- TB is a complex and multifaceted 
socioeconomic problem that needs to be addressed 
using a multisectoral approach.66 Provider- level and 
patient- level barriers need to be addressed to maximise 
the impact of advanced diagnostics. Most of the oper-
ational problems identified, such as the poor provider 
knowledge and implementation of DR- TB guidelines or 
inefficient screening or laboratory processes, are recti-
fiable, although with a substantial amount of effort and 
investment. We have identified this review as a call to 
action for all relevant players.
There is a need for more studies focusing on contex-
tual access dimensions and care cascades from more 
HBCs in SSA, as this review has highlighted a dominance 
of studies from South Africa.
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